重组人血小板生成素联合激素治疗血小板减少性紫癜的效果评价

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (0 KB) HTML (32 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究重组人血小板生成素联合激素治疗血小板减少性紫癜（ITP）的临床效果。方法选取2015年3月～2017年6月我院收治的60例ITP患者为研究对象，采用随机数字表法分为观察组和对照组各30例。对照组采用糖皮质激素治疗，观察组则在对照组基础上加用重组人血小板生成素治疗，比较两组患者治疗前后的血小板计数、血小板回升时间。结果观察组患者治疗总有效率为83.3%（25/30），显著高于对照组的66.7%（20/30），差异有统计学意义（P＜0.05）；观察组患者治疗后的血小板计数改善显著高于对照组，且血小板上升时间显著短于对照组，差异有统计学意义（P＜0.05）。结论重组人血小板生成素联合激素治疗ITP的效果确切，能够快速促进血小板的生成，值得在临床上推广和应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李旭丹

关键词 ：血小板减少性紫癜, 重组人血小板生成素, 糖皮质激素, 疗效

Abstract：ObjectiveTo investigate the clinical efficacy of Recombinant Human Thrombopoietin combined with Hormone in the treatment of thrombocytopenic purpura （ITP）.Methods60 patients with ITP who treated in our hospital from March 2015 to June 2017 were selected as subject,they were randomly divided into observation group and control group,with 30 cases in each group.The control group was treated with Glucocorticoid therapy,and the observation group was used Recombinant Human Thrombopoietin treatment based on the control group,and platelet count,platelet recovery time were compared between the two groups before and after treatment.ResultsThe total efficiency of the observation group was 83.3%(25/30),significantly higher than the control group 66.7%(20/30),the difference was statistically significant(P＜0.05);patients in the observation group after treatment improved the platelet count was significantly higher than the control group,and platelet rise time significantly lower than the control group,the difference was statistically significant(P＜0.05).ConclusionRecombinant Human Thrombopoietin combined with Hormone therapy is effective in the treatment of ITP,which can promote the production of platelets rapidly and deserve clinical application and promotion.

Key words： Thrombocytopenic purpura Recombinant Human Thrombopoietin GLucocorticoid Curative effect

作者简介: 李旭丹（1982-），男，本科，主治医师，研究方向：血液系统疾病的诊治

引用本文:

李旭丹. 重组人血小板生成素联合激素治疗血小板减少性紫癜的效果评价[J]. 中国当代医药, 2017, 24(32): 23-25.
LI Xu-dan. Efficacy of Recombinant Human Thrombopoietin combined with Hormone in the treatment of thrombocytopenic purpura. 中国当代医药, 2017, 24(32): 23-25.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I32/23

[1]	中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识（2012年版）[J].中华血液学杂志，2012，33（11）：975-977.
[2]	顾史洋，庄静丽，邹善华，等.重组人血小板生成素联合糖皮质激素治疗重症新诊断原发免疫性血小板减少症患者临床观察[J].中华血液学杂志，2013，34（10）：883-886.
[3]	杜以萍，张充力，毕珍宁.糖皮质激素联合重组人促血小板生成素治疗特发性血小板减少性紫癜[J].血栓与止血学，2014，20（2）：79-80.
[4]	支雅军，乐静，万斌，等.重组人血小板生成素联合糖皮质激素治疗难治性特发性血小板减少性紫癜的疗效观察[J].现代实用医学，2013，25（4）：417-418.
[5]	郑迎春，李佳慧.特发性血小板减少性紫癜诊断和治疗效果探讨[J].中国继续医学教育，2016，8（28）：201-202.
[6]	McMIllan R，Wang L，Tomer A，ET AL.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J].Blood，2004，103（4）：1364-1369．
[7]	Molineux G，Newland A.Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia： from bench to bedside[J].Br J Haematol，2010，150（1）：9-20．
[8]	Saleh MN，Bussel JB，Cheng G，et al.Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia： results of the long-term，open-lable EXTEND study[J].Blood，2013，121（3）：537-545．
[9]	Wang S，Yang R，Zhou P，et al.A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J].Int J Hematol，2012，96（2）：222-228．
[10]	Provan D Stasi R，Newland AC，et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood，2010，118（2）：168-186．
[11]	Bussel JB，Kuter DJ，Pullarkat V，et al．Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP[J].Blood，2009，113（10）：2161-2171．
[12]	刘隽，程毅敏，邹丽芳，等.重组人血小板生成素治疗老年慢性免疫性血小板减少性紫癜的疗效观察[J].中国临床医学，2013，20（3）：390-392.
[13]	徐颜美，邓立彬，王小中.原发免疫性血小板减少性紫癜的遗传学研究进展[J].重庆医学，2014，43（13）：1646-1648.
[14]	孔凡霞，陈晓乐，杜秋香，等.重组人血小板生成素联合糖皮质激素和环胞素A治疗免疫性血小板减少症的研究[J].中国医学装备，2015，12（5）：36-38.
[15]	王厚才.免疫性血小板减少性紫癜发病的免疫机制[J].国际输血及血液学杂志，2011，34（3）：127.
[18]	Gernsheimer T.Chronic idiopathic thrombocytopenic purpura： mechanisms of pathogenesis[J].Oncologist，2009，14（1）：12-21.
[16]	Rocha AMC，Souza C，Rocha G A，et al.The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia[J].Haematologica，2011，9600（10）：1560-1564.
[17]	Olsson B，Andersson PO，Jernas M，et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J].Nat Med，2003，9（9）：1123-1124.